Occurrence of XXXX in recently diagnosed @entity4932 : a prospective study.

@entity1 @entity627 @entity625 @entity1596 @entity4932
OBJECTIVE: To examine the occurrence and characteristics of @entity1596 in @entity1 with recently diagnosed @entity4932 ( @entity4932 ). DESIGN: A prospective observational case series. @entity1 /METHODS: The study covered the new cases detected with @entity4932 (426 @entity1 ), all of whom were referred to an ophthalmologic consultation during 1989 to 1996 at the Pediatric Department of the @entity627 Foundation Hospital, Heinola, Finland. MAIN OUTCOME MEASURES: The @entity1 with @entity4932 were followed by ophthalmologic and pediatric examinations two to four times a year. The type and course of @entity625 and presentation and characteristics of @entity1596 were examined prospectively. RESULTS: @entity1596 was detected in 104 of 426 @entity1 (24%). Two thirds of all @entity1 and the same proportion of those with @entity1596 were @entity1 . Proportionally, @entity1596 was found to be as common among @entity1 with @entity4932 (27%) as among those with seronegative @entity625 (25%). Antinuclear antibodies (ANA) were detected significantly more frequently in @entity1 with @entity1596 (66%) than among those without @entity1596 (37%) (P < 0.001). The @entity1596 was asymptomatic in 99 cases; only 5 @entity1 had episodes of acute anterior symptomatic @entity1596 . @entity1596 was found before or within 3 months from the onset of recent @entity625 in 51 of 104 @entity1 (49%) and later on in 53 of 104 @entity1 (51%). The mean age at diagnosis of @entity1596 was 5.9 years (range, 1.1-17.7; median, 4.9 years). The mean period from the diagnosis of @entity4932 to the diagnosis of @entity1596 was 1.1 years (range, -2.4-6.5; median, 0.3 years). The mean age at diagnosis of @entity4932 was 4.8 years (range, 0.6-15; median, 3.2 years) among those with @entity1596 and 7.3 years (range, 0.9-16; median, 6.7 years) among those who did not have it (P < 0.001). @entity1596 was ongoing in 63 @entity1 at the end of the follow-up period. The mean follow-up time was 4.5 years (range, 0-9.7) for all @entity1 and 5.6 years (range, 1.3-9.6) for those with @entity1596 . In most instances, the visual prognosis was good. In 25 of 104 @entity1 (24%) one or more complications of @entity1596 were found, but in only three @entity1 did the visual acuity decrease to 20/60 or less, and none became blind. All the other @entity1 had visual acuity > or = 20/40. CONCLUSIONS: In this @entity1 group, @entity1596 in @entity4932 frequently appeared very early after the onset of @entity625 . The @entity1596 was significantly more common in @entity1 with an early onset of @entity625 combined with ANA positivity. The proportion of @entity1 with @entity1596 was as large in those with @entity625 as in those with @entity4932 , with no predilection to @entity1 .
